Flexion Therapeutics Profile

USD 0.52  2.21%

Flexion Therapeutics exotic insider transaction detected

Flexion Therapeutics Inc insider trading alert for general transaction of common stock by Samuel Colella, the corporate stakeholder, on March 11, 2018. This event was filed by Flexion Therapeutics Inc with SEC on 2016-11-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Flexion Therapeutics Summary

Flexion Therapeutics Inc (FLXN) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 251 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 864.5 M. Flexion Therapeutics Inc conducts business under Healthcare sector and is part of Drugs - Generic industry. This company has 37.62 M outstanding shares of which 10.35 M shares are currently shorted by private and institutional investors with about 6.06 trading days to cover. Flexion Therapeut currently holds about 392.44 M in cash with (107.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.43.
Check Flexion Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Exposer

PriceHorizonTargetAbove OddsBelow Odds
 22.98 30 days 22.98  under 95% about 5.72%
Based on normal probability distribution, the odds of Flexion Therapeutics to move above current price in 30 days from now is under 95%.

Top Holders

Selected Flexion Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Flexion Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 68% 
Equity ratings for Flexion Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drugs - Generic classification in USA and traded on NASDAQ General Markets. It employs 251 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameFlexion Therapeutics Inc
CEO, Co-Founder, Board MemberMichael ClaymanView All
Thematic ClassificationPharmaceutical ProductsView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address10 Mall Road
ExchangeNASDAQ General Markets
CIK Number01419600.0
IndustryDrugs - Generic
Contact Number781 305 7777
CurrencyUSD - US Dollar


Flexion Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
35.0Strong Buy4Odds
Flexion Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Flexion Therapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Flexion Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.67March 9, 2017
Flexion Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Flexion Therapeutics Corporate Directors
Sandesh Mahatme Director
Scott Canute Director, MBA
Ann Merrifield Director